cagrisema cagrilintide semaglutide phase 3 2025 vs Tirzepatide: 23% Weight Loss in Trial Novo Nordisk's CagriSema 2.4 mg
Description
Pooya S, Blaise S, Garcia MM, Giudicelli J, Alberto J-M, Guant-Rodriguez R-M, Jeannesson E, Gueguen N, Bressenot A, Nicolas B

Notman, R., Noro, M., OMalley, B
01022-6/asset/a38873d9-5999-4e60-a3fc-c2fd1cbeca3d/main.assets/gr2_lrg.jpg)
If you experience suspected side effects from weight loss injections, report them via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app)
00125-7/asset/25d10da2-038c-4d13-b485-c9856810af68/main.assets/gr3_lrg.jpg)
doi:10.1016/0003-9861(55)90070-9
01751-7/asset/f8ffb968-301f-4b4c-9c56-cfb01106603a/main.assets/gr2a_lrg.jpg)